SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
21st Mar 20127:00 amPRNUnaudited Preliminary Results
19th Mar 20127:00 amPRNNotification of Preliminary Results
10th Feb 20127:00 amPRNSilence Therapeutics Announces Board Changes and New CEO
27th Jan 20124:40 pmRNSSecond Price Monitoring Extn
27th Jan 20124:35 pmRNSPrice Monitoring Extension
26th Jan 20127:00 amPRNTR-1: Notifications of Major Interest in Shares
23rd Jan 20127:00 amPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Jan 20127:00 amPRNSilence signs collaboration with miRagen Therapeutics
6th Jan 20127:00 amPRNResearch and Development Collaboration Update
30th Dec 20117:00 amPRNTotal Voting Rights
20th Dec 20114:40 pmRNSSecond Price Monitoring Extn
20th Dec 20114:35 pmRNSPrice Monitoring Extension
20th Dec 20117:00 amPRNAdditional Listing
12th Dec 20117:00 amPRNPositive Response by USPTO
9th Dec 20114:40 pmRNSSecond Price Monitoring Extn
9th Dec 20114:35 pmRNSPrice Monitoring Extension
7th Dec 20111:27 pmPRNPositive outcome from oral hearing at Patent Office
22nd Nov 20114:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20114:35 pmRNSPrice Monitoring Extension
8th Nov 20117:00 amPRNSilence Therapeutics provides update
24th Oct 20117:00 amPRNCollaboration with Mirna Therapeutics
14th Oct 20117:00 amPRNGrant of options
3rd Oct 20117:00 amPRNDirectors’ share purchases
21st Sep 20117:00 amPRNAppointment of Chief Business Officer
21st Sep 20117:00 amPRNInterim Results for the Six Months Ended 30 June 2011
20th Sep 20117:00 amPRNAppointment of Chief Executive Officer
14th Sep 201110:32 amPRNNotice of Results
13th Sep 20114:40 pmRNSSecond Price Monitoring Extn
13th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20119:24 amPRNSilence & InteRNA Technologies collaboration
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn
5th Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20114:40 pmRNSSecond Price Monitoring Extn
1st Sep 20114:35 pmRNSPrice Monitoring Extension
31st Aug 20114:40 pmRNSSecond Price Monitoring Extn
31st Aug 20114:35 pmRNSPrice Monitoring Extension
26th Aug 20114:40 pmRNSSecond Price Monitoring Extn
26th Aug 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20114:41 pmRNSSecond Price Monitoring Extn
23rd Aug 20114:35 pmRNSPrice Monitoring Extension
22nd Aug 20114:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20114:35 pmRNSPrice Monitoring Extension
18th Aug 20114:41 pmRNSSecond Price Monitoring Extn
18th Aug 20114:35 pmRNSPrice Monitoring Extension
12th Aug 20114:40 pmRNSSecond Price Monitoring Extn
12th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20114:40 pmRNSSecond Price Monitoring Extn
11th Aug 20114:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.